PDF icon Download PDF
Semin Neurol 2023; 43(03): 323-336
DOI: 10.1055/a-2105-6614
Review Article

Endovascular Management of Brain Arteriovenous Malformations

Julien Ognard
1   Department of Interventional Neuroradiology, Brest University Hospital, Brest, France
2   Inserm, UMR 1101 (Laboratoire de Traitement de l'Information Médicale-LaTIM), Université de Bretagne Occidentale, Brest, France
,
Elsa Magro
2   Inserm, UMR 1101 (Laboratoire de Traitement de l'Information Médicale-LaTIM), Université de Bretagne Occidentale, Brest, France
3   Department of Neurosurgery, Brest University Hospital, Brest, France
,
Jildaz Caroff
4   Department of Interventional Neuroradiology, NEURI Brain Vascular Center, Bicêtre Hospital, APHP, Paris Saclay University, Le Kremlin-Bicêtre, France
,
Vivek Bodani
5   Division of Neuroradiology, Joint Department of Medical Imaging, Toronto Western Hospital and University of Toronto, Toronto, Ontario, Canada
,
Pascal John Mosimann   *
5   Division of Neuroradiology, Joint Department of Medical Imaging, Toronto Western Hospital and University of Toronto, Toronto, Ontario, Canada
,
Jean-Christophe Gentric   *
1   Department of Interventional Neuroradiology, Brest University Hospital, Brest, France
6   Inserm, UMR 1304 (GETBO), Western Brittany Thrombosis Study Group, Université de Bretagne Occidentale, Brest, France
› Author Affiliations
› Further Information
   Permissions and Reprints
Preview

Abstract

Due to the risk of cerebral hemorrhage, and its related morbidity–mortality, brain arteriovenous malformations (bAVMs) are a rare and potentially life-threatening disease. Despite this, there is only one randomized controlled trial on bAVM management, A Randomized trial of Unruptured Brain Arteriovenous malformations (ARUBA). The results of the ARUBA trial favor a noninterventional approach in the case of an unruptured bAVM; however, implementation of these findings is challenging in daily practice. Instead, management of bAVM relies on multidisciplinary discussions that lead to patient-specific strategies based on patient preferences, local expertise, and experience in referral centers. Considering the diverse patterns of presentation and numerous treatment modalities, implementing standardized guidelines in this context proves challenging, notwithstanding the recommendations or expert opinions offered. Endovascular treatment (EVT) of bAVM can be curative, or can serve as an adjunct treatment prior to surgery or radiosurgery (“pre-EVT”). EVT practice is in constant evolution (i.e., venous approach, combination with surgery during the same anesthesia, etc.). Liquid embolic agents such as ethylene vinyl alcohol (EVOH) copolymer and cyanoacrylates (CYA), and their method of injection to increase bAVM occlusion have also benefited from technical evolutions such as the use of adjunctive flow arrest techniques (mini balloons, pressure cooker technique, and multiple catheters). Further research is necessary to evaluate the advantages and disadvantages of EVT for bAVM.

Keywords

brain arteriovenous malformation - endovascular treatment - liquid embolic agent - randomized control trial

* P.J. Mosimann and J.C. Gentric contributed equally as senior authors.




Publication History

Accepted Manuscript online:
05 June 2023

Article published online:
18 August 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA